This past month on HCPLive, several important topics were covered as part of our dermatology content from March.
The list includes new trial data on psoriasis, atopic dermatitis (AD), hidradenitis suppurativa (HS), and prurigo nodularis (PN) treatment options.
The following list is a summary of these major breakthroughs covered in March in the dermatology space, with more news and updated content on these topics available on the HCPLive main news page.
1. Positive Phase 3 Trial Results for Tapinarof Cream on Atopic Dermatitis
In this HCPLive article, phase 3 data from the ADORING 2 trial indicated that about of half of AD patients treated with tapinarof, 1% showed improvement on the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADTM).
The investigators noted that tapinarof may be potential two-in-one first-line topical treatment for both atopic dermatitis and plaque psoriasis, as the new trial found the cream to be both safe and tolerable for all age groups down to 2 years.
The study results were announced by biopharmaceutical company Dermavant Sciences.
2. Positive Trial Results for Hand, Foot Eczema Patients Treated with Dupilumab
This late-breaking data was shown at the American Academy of Dermatology (AAD) 2023 conference, showing that about 40% of uncontrolled moderate-to-severe hand and foot AD patients achieved clear or almost clear skin compared to 17% with placebo.
The researchers saw improvements as early as 1 week, noting that there were substantial improvements in measures of sleep, skin pain, as well as hand eczema-related life quality. They noted that the drug was the first biologic evaluated for this particular patient population.
The data was presented by Eric Simpson, MD, the studys principal trial investigator.
3. Nemolizumab Treatment Led to Improved Skin Lesions, Itch for Prurigo Nodularis Patients
Phase 3 data from the OLYMPIA 2 trial, presented at AAD, showed that nemolizumab monotherapy improved skin lesions, itch, and sleep disturbances in adults with moderate-to-severe prurigo nodularis (PN).
The investigators reported that nemolizumab, a first-in-class, interleukin-31 receptor alpha antagonist, met all of the studys primary and key secondary endpoints.
The late-breaking results were presented by Shawn Kwatra, MD, from Johns Hopkins University School of Medicine.
4. Once Daily Roflumilast Improved Symptoms of Atopic Dermatitis in Phase 3 Trials
This late-breaking data, presented at AAD, showed that roflumilast 0.15% once-daily improved AD across multiple efficacy endpoints and produced favorable safety and tolerability in patients.
The results showed that adverse events (AEs) were reported in less than 3.5% of patients, and application site pain incidence was low. The data resulted from the INTEGUMENT-1 and INTEGUMENT-2 studies.
The results were presented by Lawrence Eichenfield, MD, from Rady Children's Hospital.
5. Phase 3 Trial Data on Bimekizumab for Patients with Hidradenitis Suppurativa
This data, also presented at AAD, indicated that a greater percentage of HS patients achieved HiSCR50 for those treated with bimekizumab compared to placebo at week 16 of the study.
The results came from the BE HEARD I and II trials investigating the selective inhibition of IL-17F and IL-17A by bimekizumb, a monoclonal IgG1 antibody.
The research was presented at the conference by lead investigator Alexa B. Kimball, MD, from Beth Israel Deaconess Medical Center.
6. Oral Roflumilast Effective, Safe in Treating Plaque Psoriasis Over 24 Weeks
In this study, oral roflumilast treatment was found to lead to significant Psoriasis Area and Severity Index (PASI) score, with 34.8% of their treatment group reached PASI75 compared to 0.0% in given placebo by week 12.
The late-breaking data on oral roflumilast, a targeted phosphodiesterase (PDE)-4 inhibitor, was presented at AAD 2023. The research team also stated that roflumilast may become a cheap alternative treatment to other psoriasis drugs with more research.
The findings were presented by Alexander Egeberg, MD, PhD, from the University of Copenhagen and Bispebjerg Hospital.
7. Oral TYK2 Inhibitor Led to Significant Skin Clearance Improvement in Psoriasis
These results showed that treatment with TAK-279 (formerly NDI-034858), an oral tyrosine kinase 2 (TYK2) inhibitor, led to significant skin clearance improvement for moderate-to-severe psoriasis patients compared to placebo, especially at a once-daily, 5 mg dose.
The phase 2b clinical trial data was shown at AAD, and the investigators demonstrated that at the highest dose of TAK-279, 33% of study participants reached complete skin clearance by week 12.
The data was presented at the conference by April W. Armstrong, MD, MPH, from USCs Keck School of Medicine.
Read this article:
Dermatology Month in Review: Highlights from March 2023 - MD Magazine
- Memorial Health System is re-opening of Department of Dermatology - Parkersburg News - October 26th, 2024 [October 26th, 2024]
- Available Therapeutics and Upcoming Advancements in Atopic Dermatitis and Prurigo Nodularis - Dermatology Times - October 26th, 2024 [October 26th, 2024]
- Sun Pharma Announces Multiple Data Presentations Highlighting its Dermatology Portfolio to be Featured at the 2024 Fall Clinical Dermatology... - October 26th, 2024 [October 26th, 2024]
- What To Look Forward To at the Fall Clinical Dermatology Conference, with Raj Chovatiya, MD, PhD - MD Magazine - October 26th, 2024 [October 26th, 2024]
- Navigating Complexities and Unmet Needs of Chronic Hand Eczema - Dermatology Times - October 26th, 2024 [October 26th, 2024]
- Schweiger Dermatology Group Expands in Florida with the Acquisition of ClearlyDerm, Adding 5 New Offices in South Florida - PR Newswire - October 26th, 2024 [October 26th, 2024]
- Leo Pharma tells doctors to 'Talk to the Hand' in new dermatology campaign - FiercePharma - October 26th, 2024 [October 26th, 2024]
- Dermatology Partners To Expand Maryland Presence With New Westminster Clinic, Hosts Free Skin Cancer Screenings For Veterans On November 11 - citybiz - October 26th, 2024 [October 26th, 2024]
- Peter Lio, MD: The Latest Perspectives on Pathophysiology and Treatment of Eczema - Dermatology Times - October 26th, 2024 [October 26th, 2024]
- Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell... - October 26th, 2024 [October 26th, 2024]
- Dermatology Patients Taking Biologics are Wary About Most Vaccines - Medpage Today - October 13th, 2024 [October 13th, 2024]
- Safe and Effective: Upadacitinib Shows Promise in PN Treatment - Dermatology Times - October 13th, 2024 [October 13th, 2024]
- SPONSORED: First Care, Heartland Dermatology team up again for free health screening event - Hays Post - October 13th, 2024 [October 13th, 2024]
- Global Dermatology Drugs Market to Worth Over US$ 50.42 Billion By 2032 | Astute Analytica - GlobeNewswire - October 13th, 2024 [October 13th, 2024]
- Working to Improve Mental Health - Dermatology Times - October 13th, 2024 [October 13th, 2024]
- Bimekizumab Demonstrates Safety and Efficacy in Elderly Patients with Psoriasis - Dermatology Times - October 13th, 2024 [October 13th, 2024]
- Analyzing Efficacy and Safety in Diverse Clinical Trials: New Roflumilast Data - Dermatology Times - October 2nd, 2024 [October 2nd, 2024]
- UCB at EADV 2024: committed to advancing care in immuno-dermatology - UCB - October 2nd, 2024 [October 2nd, 2024]
- Positive Results Reported in Roflumilast 0.15% for AD Across Diverse Populations - Dermatology Times - October 2nd, 2024 [October 2nd, 2024]
- Expert Insights Into Handling Treatment Challenges and Site-Specific Concerns in Vitiligo Management - Dermatology Times - October 2nd, 2024 [October 2nd, 2024]
- Dermatology Excimer Laser Market is expected to Double Its Size - openPR - October 2nd, 2024 [October 2nd, 2024]
- InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and... - October 2nd, 2024 [October 2nd, 2024]
- Discussing Unmet Needs Among Patients in Dermatology, with Matthew Zirwas, MD - MD Magazine - September 23rd, 2024 [September 23rd, 2024]
- Organon Moves Into Branded Dermatology With Dermavant Takeout - Scrip - September 23rd, 2024 [September 23rd, 2024]
- Dermatology Research Team Investigating the Most Common Disease Youve Never Heard About - University of Miami - September 23rd, 2024 [September 23rd, 2024]
- Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress - Business Wire - September 23rd, 2024 [September 23rd, 2024]
- Hensin Tsao, MD, PhD: TIL Therapy and Neoadjuvant Treatment for Pigmented Lesions - Dermatology Times - September 23rd, 2024 [September 23rd, 2024]
- Derm In The News: September 8-14 - Dermatology Times - September 15th, 2024 [September 15th, 2024]
- April Armstrong, MD, MPH, Shares Insights on the NPF's Psoriasis Health Indicator Report - Dermatology Times - September 15th, 2024 [September 15th, 2024]
- Nearly half of FDA-authorized AI tools may be ineffective - Dermatology Times - September 15th, 2024 [September 15th, 2024]
- Dermatology Diagnostic Devices And Therapeutics Market - openPR - September 15th, 2024 [September 15th, 2024]
- Industry Deep Dive: Dermatology Devices Market Size, Share, and Growth Forecast with Emerging Trends through 2032 - openPR - September 15th, 2024 [September 15th, 2024]
- SPROUT Trial Highlights Benefits of Apremilast for Pediatric Psoriasis - Dermatology Times - September 15th, 2024 [September 15th, 2024]
- Veterinary Dermatology Drugs Market Global Latest Trends and Insights 2024 to 2031 - openPR - September 15th, 2024 [September 15th, 2024]
- Championing equity in skin of color dermatology - Fierce healthcare - August 5th, 2024 [August 5th, 2024]
- Derm In The News: July 28-August 3 - Dermatology Times - August 5th, 2024 [August 5th, 2024]
- Interview Intersection: Expert Interviews From July 2024 - Dermatology Times - August 5th, 2024 [August 5th, 2024]
- Generation Z, Millennials Exhibit Similar Subjective Perception of Atopic Dermatitis Disease Severity - Dermatology Times - August 5th, 2024 [August 5th, 2024]
- Long-Term Efficacy and Insights from POETYK PSO-1 Studies: Implications for Psoriasis Treatment - Dermatology Times - August 5th, 2024 [August 5th, 2024]
- Laurel Dermatology emphasizes the importance of sunscreen - WDAM - July 26th, 2024 [July 26th, 2024]
- The Interplay Between Sleep Disorders and Dermatology - Dermatology Times - July 26th, 2024 [July 26th, 2024]
- Latex Gloves and the Americans With Disabilities Act - Dermatology Times - July 26th, 2024 [July 26th, 2024]
- Advanced Practice Providers Share Insights at the 2024 Society for Pediatric Dermatology Annual Meeting - Dermatology Times - July 26th, 2024 [July 26th, 2024]
- Almiralls H1 2024 Results: Almirall Delivers Strong Performance in the First Half of 2024, Achieving Net Sales Growth of 6.7% Driven by Its European... - July 26th, 2024 [July 26th, 2024]
- Arcutis Submits sNDA for Roflumilast Foam to FDA for Scalp and Body Psoriasis - Dermatology Times - July 26th, 2024 [July 26th, 2024]
- Appier and SkinX Thailand Partner to Revolutionise Dermatology Services with AI - SME Magazine - July 26th, 2024 [July 26th, 2024]
- Diagnostic dermatology market to be valued at $43.4b by 2034 - Healthcare Asia - July 26th, 2024 [July 26th, 2024]
- FDNY Partners with American Academy of Dermatology to Provide Free Skin Cancer Checks - nyc.gov - June 1st, 2024 [June 1st, 2024]
- Day 1 Recap: 2024 Fall Clinical Dermatology Conference for PAs and NPs - Dermatology Times - June 1st, 2024 [June 1st, 2024]
- Dermatology's Rosanne Paul discusses safety of foot peels - The Daily | Case Western Reserve University - June 1st, 2024 [June 1st, 2024]
- Sneak Peek: 2024 Fall Clinical Dermatology Conference for PAs and NPs - Dermatology Times - June 1st, 2024 [June 1st, 2024]
- New Dermatology Center to Open at The Grand Resort's Med Spa - businessjournaldaily.com - June 1st, 2024 [June 1st, 2024]
- Dermatology Care of Alabama goes the extra mile to give the best care - Hoover Sun - June 1st, 2024 [June 1st, 2024]
- QUIZ RECAP: Treatment and Management of Skin Cancer - Dermatology Times - June 1st, 2024 [June 1st, 2024]
- What to Know About Peptides, the Retinol Alternative Dermatologists Love | SELF - Self - June 1st, 2024 [June 1st, 2024]
- Reviewing Common and Prevalent Dermatoses in AAPI Patients - Dermatology Times - June 1st, 2024 [June 1st, 2024]
- Dermatologists Advise Against Taking Bite Of Facial Cream - The Onion - June 1st, 2024 [June 1st, 2024]
- Prescription Dermatology Therapeutics Market Drivers And Restraints Identified Through SWOT Analysis 2030 - openPR - June 1st, 2024 [June 1st, 2024]
- Derm In The News: May 19-25 - Dermatology Times - June 1st, 2024 [June 1st, 2024]
- What Gen Z Should Know About Sunscreen to Help Protect From Skin Cancer - The New York Times - June 1st, 2024 [June 1st, 2024]
- American Academy of Dermatology Association Statement on Reports on Counterfeit Injectables - Newswise - April 15th, 2024 [April 15th, 2024]
- Surface Area of IL-23's Epitope Influences Short- and Long-Term Responses for IL-23 Inhibitors in Plaque Psoriasis - Dermatology Times - April 15th, 2024 [April 15th, 2024]
- Atopic Dermatitis (Eczema): 5 Top Self-Care Tips - Everyday Health - April 15th, 2024 [April 15th, 2024]
- Derm In The News: April 7-13 - Dermatology Times - April 15th, 2024 [April 15th, 2024]
- Generative models improve fairness of medical classifiers under distribution shifts - Nature.com - April 15th, 2024 [April 15th, 2024]
- A 30-Year-Old White Female Presented With a 4-Month History of Scaly, Erythematous Patches and Plaques on Her ... - MDedge - April 15th, 2024 [April 15th, 2024]
- 9 Best Baby Eczema Creams of 2024 to Soothe Delicate Skin, According to Dermatologists - Allure - April 15th, 2024 [April 15th, 2024]
- QUIZ: Test Your Knowledge of Rosacea Etiology, Types, and Triggers - Dermatology Times - April 15th, 2024 [April 15th, 2024]
- Empowering Patients: Effective Dermatologic Treatment Selection for Hand and Feet AD - Dermatology Times - April 15th, 2024 [April 15th, 2024]
- How To Treat Strawberry Legs, According To Dermatologists - Women's Health - April 15th, 2024 [April 15th, 2024]
- Rosacea Awareness Month: Resources to Share With Your Patients - Dermatology Times - April 15th, 2024 [April 15th, 2024]
- Understanding Drug Interactions in Systemic Treatment: Impact on Atopic Dermatitis Symptoms - Dermatology Times - April 15th, 2024 [April 15th, 2024]
- Derm In The News: March 31-April 6 - Dermatology Times - April 7th, 2024 [April 7th, 2024]
- Dr. Hillary Johnson-Jahangir of Forefront Dermatology Designated as a Candela Center of Excellence - PR Newswire - April 7th, 2024 [April 7th, 2024]
- How to Boost Your Immune System While Living With Psoriasis - Everyday Health - April 7th, 2024 [April 7th, 2024]
- Im a Harvard-trained dermatologist Ive followed 3 anti-aging rules for years, Im still a fan of a drug... - The US Sun - April 7th, 2024 [April 7th, 2024]
- Cosmetic Procedures for Psoriasis: Are They Safe? - Everyday Health - April 7th, 2024 [April 7th, 2024]
- FDA Approves Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum - Dermatology Times - January 8th, 2024 [January 8th, 2024]
- Dermatology treatments can become an expensive ongoing cost. - The Mountaineer - January 8th, 2024 [January 8th, 2024]
- Dermatology treatments can become an expensive ongoing cost. - Islander News.com - January 8th, 2024 [January 8th, 2024]